ViewRay (NSDQ:VRAY) said yesterday it tapped former Spectranetics head Scott Drake as its new chief executive officer and former Spectranetics COO Shar Matin as its new COO. Before joining ViewRay, Drake served as CEO and prez of Spectranetics, which was acquired by Royal Philips (NYSE:PHG) in a deal that closed last August. Drake also serves as board chair […]
Veryan’s helical stent meets safety, efficacy endpoints after 12 months
Veryan‘s helical BioMimics 3D stent met its primary safety and efficacy endpoints in a study of 271 patients with symptomatic femoropopliteal artery disease, according to TCTMD. The device, which is shaped to mimic the natural geometry of human vasculature, compared favorably with drug-coated balloons and stents. The probability of maintaining primary patency after 12 months was […]
These 10 medtech companies care a lot about research
Among the world’s largest medtech companies, these 10 spent the largest portion of their budgets on research and development. So what have they produced? Every year, Medical Design & Outsourcing pulls financial regulatory filings and reaches out to major, companies in some cases to create a list of the 100 largest medical device companies in […]
Philips subsidiary Spectranetics recalls Bridge occlusion balloon
Royal Philips (NYSE:PHG) subsidiary Spectranetics recalled its Bridge occlusion balloon after receiving reports of blocked guidewire lumens. The Bridge device is used to temporarily block the superior vena cava for emergency control of hemorrhage. Spectranetics said the August 25 recall was prompted by nine reports of blocked guidewire lumens, although no deaths or serious injuries were […]
Philips closes $2B Spectranetics acquisition
Royal Philips (NYSE:PHG) said yesterday it closed its $2.2 billion deal to acquire US vascular intervention device maker Spectranetics (NSDQ:SPNC). With the closure, Spectranetics and its financial results will be consolidated into Philips image-guided therapy business, the company said. Philips said that Spectranetics employs over 900 individuals and is currently posting double-digit growth, with projected 2017 sales […]
Spectranetics wins FDA nod for Stellarex DCB
Spectranetics (NSDQ:SPNC) said today that its Stellarex drug-coated balloon won FDA pre-market approval. The device is designed to treat patients with peripheral arterial disease, bringing blood flow back to the superficial femoral and popliteal arteries. Get the full story at our sister site, Drug Delivery Business News.
Philips to pay $2B for Spectranetics, plans $1.7B share buyback
Royal Philips (NYSE:PHG) and Spectranetics (NSDQ:SPNC) said today that they agreed to a deal worth more than $2 billion that will see the Dutch healthcare giant take over the U.S. medical device maker. The $38.50-per-share deal values Spectranetics at $2.16 billion (€1.9 billion), including cash and debt, and is a 27% premium on SPNC’s $30.40 closing price […]
Spectranetics touts 100% survival rate in Bridge occlusion balloon study
Spectranetics (NSDQ:SPNC) today released data from a late breaking clinical trial of its Bridge occlusion balloon designed to reduce blood loss due to superior vena cava tears during lead extraction procedures, touting a 100% survival rate amongst patients treated with the balloon. The company presented 1-year clinical experience data from the study today at the Heart Rhythm […]
Spectranetics shares rise on Q4, FY2016 beat
Shares in Spectranetics (NSDQ:SPNC) rose today after the medical device maker beat expectations on Wall Street with its 4th quarter and fiscal year 2016 earnings report. The Colorado Springs, Colo.-based company posted losses of $12.6 million, or 29¢ per share, on sales of $71.9 million for the 3 months ended Dec.31, with losses on the […]
Xtant Medical CEO Goldberger steps down | Personnel Moves | February 3, 2017
Xtant Medical (NYSE:XTNT) said that CEO Dan Goldberger resigned effective Jan. 21 “to pursue other interests.” The Belgrade, Mont.-based company, which was formed after Bacterin paid $86 million for spinal implant maker X-Spine Systems, said president Carl O’Connell will step in as interim CEO while the company’s board “contemplates the permanent CEO,” according to a […]
Spectranetics touts high primary patency, low CD-TLR for Stellarex DCB data in complex cases
Spectranetics (NSDQ:SPNC) today released 12-month data from the Illumenate global study of its Stellarex drug-coated balloon in treating peripheral artery disease in superficial femoral and popliteal arteries, touting a high rate of primary patency in patients with complex lesions. The 371-patient Illumenate global study included lesions which were “highly complex,” according to the Colorado Springs, Colo.-based company, and […]
- 1
- 2
- 3
- …
- 7
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube